Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.94 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,259
Open 16.94
Bid (Size) 16.90 (1)
Ask (Size) 16.91 (1)
Prev. Close 16.94
Today's Range 16.94 - 16.94
52wk Range 12.46 - 22.80
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Performance

YTD
-20.5%
-20.5%
1 Month
+27.3%
+27.3%
3 Month
+2.2%
+2.2%
6 Month
+2.7%
+2.7%
1 Year
+0.8%
+0.8%

More News

Read More
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Earnings Scheduled For May 7, 2025
Via Benzinga
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Via The Motley Fool
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Why Teva Pharmaceutical Stock Is Soaring Today
Via The Motley Fool
Topics Earnings Stocks
Exposures Financial US Equities
Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
Via Benzinga
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report
Via Investor's Business Daily
Topics Government
Exposures Political
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Via Benzinga
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
What Does the Market Think About Teva Pharmaceutical Indus?
Via Benzinga
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now
Via The Motley Fool
Topics Economy Government Stocks
Exposures Economy Interest Rates Political
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
Via The Motley Fool
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.
Via GlobeNewswire
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now
Via The Motley Fool
Teva Releases Q1 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?
The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 16.94
When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 05/16/25 07:00 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 18.81B
How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?
Teva Pharmaceutical Industries Limited American Depositary Shares has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.